Bigna Jean Joel R, Bahebeck Jean, Sobngwi Eugène, Mbanya Jean Claude
Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, P,O, Box 1364, Yaoundé, Cameroon.
BMC Res Notes. 2014 Feb 24;7:104. doi: 10.1186/1756-0500-7-104.
Currently, there is no value for the definition of abdominal obesity by measuring waist circumference in the Sub-Saharan Africa. Several definitions of metabolic syndrome (MS) have disparities concerning use of waist circumference, including International Diabetes Federation (IDF), American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI) and National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII) definitions. The aim of the study was to determine what value of waist circumference should be used and whether to use it as obligatory criterion in the metabolic syndrome in case of peripheral arterial disease (PAD).
We conducted a case-control study in Cameroon. We included patients with diabetic foot and type 2 diabetes and excluded those with an Ankle Brachial Index (ABI) > 1.3. Cases were defined as patients with ABI ≤ 0.9 and controls with ABI > 0.9. The significant p value was < 0.05 and odds ratio (OR) with 95% confidence interval was used to measured risk for have PAD with MS.
We included 19 cases and 48 controls. The risk for having PAD with MS are for the IDF: OR = 4.7 (1.4-15.1), p = 0.008, for the AHA/NHLBI: OR = 5.8 (1.5-22.5), p = 0.007, for the NCEP-ATPIII: OR = 1.8 (0.6-5.6), p = 0.286.
Abdominal obesity should be defined according to the recommendations of the IDF and AHA/NHLBI and should not be an obligatory criterion in the definition of MS for research risk to have PAD on sub-Saharan Africa.
目前,在撒哈拉以南非洲地区,通过测量腰围来定义腹型肥胖尚无定论。代谢综合征(MS)的几种定义在腰围的使用上存在差异,包括国际糖尿病联盟(IDF)、美国心脏协会/国家心肺血液研究所(AHA/NHLBI)以及美国国家胆固醇教育计划成人治疗组第三次报告(NCEP-ATPIII)的定义。本研究的目的是确定在周围动脉疾病(PAD)情况下,应采用何种腰围值以及是否应将其作为代谢综合征的强制性标准。
我们在喀麦隆进行了一项病例对照研究。纳入患有糖尿病足和2型糖尿病的患者,并排除踝臂指数(ABI)>1.3的患者。病例定义为ABI≤0.9的患者,对照组为ABI>0.9的患者。显著性p值<0.05,采用比值比(OR)及95%置信区间来衡量患有MS的PAD风险。
我们纳入了19例病例和48例对照。对于IDF,患有MS的PAD风险为:OR = 4.7(1.4 - 15.1),p = 0.008;对于AHA/NHLBI,OR = 5.8(1.5 - 22.5),p = 0.007;对于NCEP-ATPIII,OR = 1.8(0.6 - 5.6),p = 0.286。
腹型肥胖应根据IDF和AHA/NHLBI的建议来定义,在撒哈拉以南非洲地区,对于研究患有PAD的风险而言,腹型肥胖不应作为代谢综合征定义中的强制性标准。